Many tests on dogs and other animals cause unimaginable suffering. They can translate poorly into effective treatments and cures for human diseases or provide safety and efficacy data that is not relevant to humans.
You may be interested in these active petitions
Over 90% of drugs that appear safe and effective in animals do not go on to receive FDA, USA approval.
In 2023, 2,605,528 animals were used for the first time in scientific procedures incl. 2,477 dogs & 1,815 primates. Animals are bred & housed in bleak conditions and then used in tests that can cause immense physical and psychological suffering. We think government-led action is required to radically divert funding and evolve policy to implement the use of existing and the development of new Non-Animal Methodologies (NAMS). We believe the current testing paradigm is failing both animals and humans and is holding back medical advances.
Thursday 13th November 2025
The use of animals for development of products for human use remains necessary. The Government therefore does not agree to end testing on dogs and other animals for testing and research purposes.
Our published Replacing Animals in Science strategy (https://www.gov.uk/government/publications/replacing-animals-in-science-strategy) will accelerate the roll out of safe and effective alternatives to phase out animal testing in all but exceptional circumstances, delivering on our manifesto pledge to “partner with scientists, industry, and civil society as we work towards the phasing out of animal testing". By streamlining the process for bringing alternatives forward, the Government will accelerate our transition away from animal use, while continuing to support crucial research and innovation.
Scientific advances make the prospects for change better than they have ever been, and we are supporting the acceleration of advances in biomedical science and technologies, to reduce reliance on the use of animals in research. This includes stem cell research, cell culture systems that mimic the function of human organs, imaging and new computer modelling and AI techniques based on very large data sets.
The strategy is backed by £75m of funding to accelerate safe and effective alternative methods, including £30m for the UK Centre for the Validation of Alternative Methods (UKCVAM) – a new centre to make the path to regulatory approval for new alternatives as straightforward as possible. It also includes £30m for a preclinical translational models hub – an institute that will bring together data, technology and expertise to promote collaboration between researchers.
The strategy includes a target that aims to use validated alternative methods to reduce the use of dogs and non-human primates in dedicated pharmacokinetic (PK) studies for human medicines by at least 35% by 2030. The strategy also sets a target to aim to use validated alternative methods to reduce the use of non-human primates and dogs in dedicated cardiovascular safety studies by at least 50% by 2030.
The strategy builds on our current approach, to actively support and fund the development and dissemination of techniques that replace, reduce and refine the use of animals in research (the 3Rs), and to ensure that the UK continues to have a robust regulatory system for licensing animal studies and enforcing legal standards. The UK has a world leading reputation for the delivery of the 3Rs. UK Research and Innovation (UKRI) provides core funding for the National Centre for 3Rs (NC3Rs), which works nationally and internationally to drive the uptake of 3Rs technologies and ensure that advances in the 3Rs are reflected in policy, practice and regulations on animal research.
The Government will continue to support the appropriate use of animals where reliable and effective alternatives are not yet available. Animal testing is required by all global medicines regulators, including the UK’s Medicine and Healthcare Products Regulatory Agency (MHRA). However, we are determined to work with regulators and scientists as we move towards phasing out the use of animals. Enabling the properly regulated use of animals, while we move away from animal testing, is essential to improving the health and lives of humans and animals and to the safety and sustainability of our environment.
The argument claiming over 90% of drugs fail in human trials, despite being tested on animals, disregards drugs that are tested on animals and found not to be suitable for use in human clinical trials. Drugs fail for a variety of reasons and animals are used for safety screening as well as efficacy modelling. Moreover, not all types of drugs fail at the same rate. Many do better and success rates vary widely by treatment type.
The welfare of animals in science is ensured by the Animals (Scientific Procedures) Act (ASPA, 1986) and enforced by the Animals in Science Regulation Unit (ASRU). The use of animals in science is highly regulated, including a three-tier system of licensing, which licenses each establishment, project and individual involved in performing regulated procedures involving animals. The UK Home Office regulator conducts an integrated assessment of the compliance of all licence holders, including on-site inspections. The Government has published and enforces standards for the care and accommodation of all animals bred, supplied or used for scientific purposes.
ASPA mandates the development and application of alternative methods, including non-animal methods, as part of implementation of the 3Rs (the Replacement, Reduction and Refinement of animals used in research). Under ASPA, research which uses animals is only conducted where there is no alternative available, using the fewest number of animals and procedures. Until full replacement of the use of animals in science is possible, the UK’s support of refinement approaches, led by the NC3Rs, works to reduce animal suffering as much as possible.
Department for Science, Innovation & Technology